c. The Company has one class of equity shares having a par value of Rs. 10/- each. Each shareholders eligible for one vote per share held. In the eventof liquidation, the equityshareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

25. The Company has not paid any remuneration to the directors during the year hence no requirement of compliance of provisions of section 196, 197, 203 and other applicable provisions of the Companies Act 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with the Schedule V of the Companies Act 2013.

27. The debit and credit balances standing in the name of parties are subject to confirmation from them.

28. In the opinion of the Board of Directors, the current assets, loans & advances are fully realizable at the value stated, if realized in the ordinary course of business. The provisions for all known liabilities are adequate in the opinion of board.

29. Employee Benefits

A. Defined Contribution Plan

The Company has contributed to Employee Provident Fund, under defined contribution plans. The provident fund is operated by the Regional Provident Fund Commissioner.

B. Defined Benefit Plan

The present value obligation in respect of gratuity & Leave Encashment are determined based on actuarial valuation using the projected unit credit method, which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The summarized positions of various defined benefits are as under:-

32 Financial instruments

(i) Fair values hierarchy

Financial assets andfinancial liabilities measured atfairvalue in the statement of financial position are classified i nto three Levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as foll ows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data rely as little as possible on entity specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

The management assessed that cash and cash equivalents, trade receivables, other financial assets, trade payables and other current financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Other non-current financial assets hence their carrying a mounts are also considered a reasonable approxi mation of their fair values.

Financial risk management

The Company's activities expose it to market risk, liquidity risk and credit risk. The Company's board of di rectors has overall responsibilityfortheestablishment and oversight of the Company's risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

A) Credit risk

Credit risk is the risk thata counterpartyfails to discharge an obligation to the company.The companyis exposed to this risk forvarious financial instruments, for example by granting loans and receivables to customers, placing deposits, etc. The company's maximum exposure to credit risk is limited to the carrying amount of followi ng types of financial assets.

- cash and cash equivalents,

- trade receivables,

- loans & receivables carried at amortised cost, and

- deposits with banks

Credit risk management

Credit risk rating

The Companyassesses and manages credit risk based on internal credit rating system, continuouslymonitoring defaults of customers and other counterparties, identified eitherindividuaMyorbythecompany, and incorporatesthis information into its credit risk controls. Internal credit rating is performed for each class of financial instruments with different characteristics. The Company assigns the following credit ratings to each class of financial assets based on the assumptions, i npu ts a n d fa cto rs s pe ci fi c to th e cl a s s o f fi n a n ci a l a s s e ts .

Cash & cash equivalents and bank deposits

Credit risk relatedto cash and cash equivalents and bank deposits is managed by only accepting highly rated banks and diversifying bank deposits and accounts in different banks.

Trade receivables

Company's trade receivables are considered doubtful and a ccord ingly 25% expected credit losses are recognised on such receivables.

Other financial assets measured at amortised cost

Other financial assets measured atamortized costincludes advances to employees. Credit risk related to these otherfinancial assets is managed bymonitoring the recoverability of such amounts continuously, while at the same time internal control system in place ensure the amounts are within defined limits.

Liquidity risk

Prudent liquidityrisk management implies mai nta ining sufficientcash and marketable securities and the availabilityof funding through an adequate amountof committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.

Managementmonitors rollingforecasts ofthe Company's liquidityposition and cash and cash equivalents on the basis of expected cash flows. The Company takes i nto account the liquidityof the ma rket in which the entity operates. In addition,the Company's liquidity management policy i nvolves projecting cash fl ows in major currencies and considering the level of liquid assets necessaryto meetthese, monitoring balance sheet liquidityratios againstinternal and external regulatory requirements and maintaining debt financing plans.

Maturities of financial liabilities

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

Market risk Interest rate risk

The Company is not exposed to changes in market interest rates.

Price risk Exposure

The Company's exposure to price risk arises is nil Capital management

The Company' s capital management objectives are

- to ensure the Company's ability to continue as a going concern

- to provide an adequate return to shareholders

Management assesses the Company's capital requirements in order to maintain an efficient overall financing structure. This takes into account the subordination levels of the Company's various classes ofdebt.The Companymanages the capital structure and makes adjustments to it in the lightofchanges in economic conditions and the risk characteristics of the underlying assets.

35. INVESTMENTS

The company has misplaced/lost the share certificates of the investments made by it in unquoted equity shares of other companies during the shifting of its records. Hence the company is unable to locate its investments made in the unquoted equity shares as the same are not physically held by the company at present. Despite sending multiple requests to the companies in which it has made investments for issue of duplicate share certificates, the same have not yet been entertained and till date the company has not received any reply from these companies. In addition to this, the company is working towards determining the fair market value of its investments to ensure the compliance with IND AS in true letter and spirits.

36. The company is in the process of getting its name changed in the records of BSE Ltd & ASE, where the shares of the company are listed and the necessary formalities in this regard will be completed soon.

37. The company has applied for renewal of its Drug Manufacturing Licences before the term of its expiry with the Food & Drugs Administration (FDA), Panchkula, for manufacturing pharmaceutical and allied products and the same is under consideration at the end of the FDA. The management of the company firmly believes that the company would be able to restart its business operations as the company is getting quotes from the prospective buyers & the management is of the opinion that the new deals would be finalized soon. Further, the management of the company is also exploring the market and business opportunities and is putting necessary efforts in this respect so that the operations of the company can be started again.

38. Annual Listing Fees of BSE is unpaid for the F.Y. 2021-22, 2022-23, 2023-24 & 2024-25. The management of the company is trying to arrange the necessary funds and believes that all the outstanding dues of BSE shall be cleared soon.

39. Necessary disclosures under Micro, Small and Medium Enterprises Development Act 2006, could not be considered for previous years as the relevant information to identify the suppliers who were covered under the said Act were not received from such parties during the previous years.

41. Title Deeds of immovable Property: All title deeds of immovable properties are held in the name of the Company.

42. Revaluation of Property, Plant and Equipment: During the financial year, the Company has not re-valued any of its Property, Plant & Equipment.

44. Benami Properties : No proceedings has been initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988.

45. Borrowings from Banks/FI on the basis of security of Current Assets: Company had no working capital limit with bank hence no

requirement of submission of quarterly statement to bank was applicable.

46. The company has not been declared as willful defaulter by any bank of financial institution or any other lender.

47. Transactions with Struck-off Companies: The Company has not entered into any transactions with struck off companies under

section 248 of the Companies Act 2013 or Section 560 of Companies Act 1956.

48. Registration of Charges or Satisfaction: During the year, company does not have any outstanding Charges.

49. Compliance with layers of the companies:-

The company has no layers of companies prescribed under Clause (87) of the Act read with Companies (Restriction on number of Layers) Rules 2017.

50. Scheme of Arrangement : During the year, the company has not entered into any scheme or arrangement in terms of Section 230 to 237 of the Companies Act 2013.

51. During the year no income was surrendered or disclosed as income in the tax Assessments.

52. Use of Borrowed Funds: During the year Company has not borrowed any funds from banks and Financial Institutions.

53. The company has not dealt in Crypto Currency during the year.

54. The Company has not advanced or loaned or invested funds to any other person or entities with an understanding that the intermediary will invest or provide any guarantee, security or the like to or on behalf of ultimate beneficiaries.

55. The Company has not received any fund from any person (s) or entity(s), including foreign entities (Funding party)

with the understanding that the company shall directly or indirectly invest or provide any guarantee, security or the like to or on behalf of funding party.

56. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

57. In terms of Section 135(1) of the Companies Act, 2013, the provisions of Corporate Social Responsibility are not applicable to the Company.

58. In the opinion of the Board, all current assets have a value on realization in the ordinary course of business which is equal to the amount at which they are stated in financial statements.

59. Additional information, to the extent applicable, required under paragraphs 5 (viii) (c) of general instructions for preparation of the Statement of profit & Loss as per schedule III to the Companies Act, 2013

60. The Company is engaged primarily in pharmaceuticals business and there are no separate reportable segments as per IND AS-108.

61. There are no subsequent events that have occurred after the reporting period till the date of this standalone financial statements.

62. Previous year figures have been regrouped, rearranged wherever necessary to correspond with the current year's classification/disclosure.